Redhill Biopharma Ltd.
RDHL
|
$0.4519
7.39%
6.88%
330K
|
Health Technology
(0.0% 1d) (-11.4% 1m) (-83.6% 1y) (0.0% 2d) (15.4% 3d) (11.3% 7d) (38.98% volume)
Earnings Calendar:
Market Cap: $ 398,458
http://www.redhillbio.com
Sec Filling | Patents | 182 employees
(IL) RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company’s subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
gastrointestinal israel urea treatment
add to watch list Paper trade email alert is off
Press-releases
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Published: 2024-04-08 (Crawled : 13:30) - prnewswire.com
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: -1.5%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.76%
H: 0.72%
C: 0.54%
biopharma results
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: -5.2%
H: 4.9%
C: 3.92%
million direct offering biopharma market
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: 1.1%
H: 3.68%
C: 1.65%
talicia patent
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: 5.02%
H: 1.56%
C: -11.9%
opaganib
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
Published: 2024-01-26 (Crawled : 18:00) - prnewswire.com
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: -5.6%
H: 13.47%
C: 10.91%
million direct offering biopharma
RedHill Biopharma Announces $8 Million Registered Direct Offering
Published: 2024-01-25 (Crawled : 21:00) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: -31.9%
H: 0.61%
C: -11.68%
million direct offering biopharma
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
Published: 2024-01-25 (Crawled : 12:00) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: -31.9%
H: 0.61%
C: -11.68%
talicia patent treatment grant
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Published: 2023-12-20 (Crawled : 20:00) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: 9.09%
H: 20.83%
C: -2.78%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.21%
H: 0.15%
C: -1.34%
rhb-107 ebola opaganib show
Proton Pump Inhibitors (PPIs) Market to grow by USD 807.89 million from 2023-2028 | North America to account for 36% of market growth - Technavio
Published: 2023-12-19 (Crawled : 07:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.81%
H: 0.0%
C: 0.0%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 1.22%
H: 1.88%
C: 0.94%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: 0.0%
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: 0.82%
H: 8.94%
C: 7.32%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.5%
H: 0.99%
C: 0.43%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.17%
H: 0.67%
C: -0.09%
america growth market
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: 2023-12-12 (Crawled : 12:00) - prnewswire.com
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: -2.24%
H: 6.87%
C: 0.76%
nasdaq biopharma
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10